{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:34:25Z","timestamp":1785551665646,"version":"3.56.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022. The prescribed defined daily doses (DDD) and the costs per defined daily dose for the 10 medicines were taken from the Arzneiverordnungsreport (AVR) from 1986 to 2023, and the changes in prescribing behavior and their causes were analyzed. The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. There are many different reasons for an increase in prescriptions, such as the introduction of generics, a positive study, or a price reduction. Further reasons for an increase in prescriptions are an extension of the indication or the recall of a competing medicine. A change in guidelines or the increasing treatment of laboratory values without clinical symptoms can also lead to an increase in prescriptions. There are also many different reasons for a drop in prescriptions, such as the generic launch of a competitor medicine or a positive study for a competitor medicine. Other reasons for a drop in prescriptions are a negative study or a discussion about the use of a drug. Sometimes, the reasons for prescription changes are also irrational. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide.<\/jats:p>","DOI":"10.1007\/s00210-024-03615-5","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T06:45:15Z","timestamp":1732171515000},"page":"5509-5529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis"],"prefix":"10.1007","volume":"398","author":[{"given":"Lennart","family":"Schr\u00f6der","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"3615_CR1","unstructured":"BfArM (2018) Valsartan: BfArM recommends switching to medicines not affected by the recall. Press release 6\/18 from 13.07.2018"},{"key":"3615_CR2","doi-asserted-by":"publisher","unstructured":"Bindel LJ, Seifert R (2024a) Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03171-y","DOI":"10.1007\/s00210-024-03171-y"},{"key":"3615_CR3","doi-asserted-by":"publisher","unstructured":"Bindel LJ, Seifert R (2024b) Daily defined dose costs have stronger influence on antibacterial drug prescriptions in Germany than bacterial resistance: economic factors are more important than scientific evidence. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03435-7","DOI":"10.1007\/s00210-024-03435-7"},{"issue":"S1","key":"3615_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hec.4108","volume":"29","author":"KE Blankart","year":"2020","unstructured":"Blankart KE, Stargardt T (2020) The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany. Health Economics 29(S1):63\u201382. https:\/\/doi.org\/10.1002\/hec.4108. lastaccessed06.09.2024","journal-title":"Health Economics"},{"issue":"5","key":"3615_CR5","doi-asserted-by":"publisher","first-page":"e0301716","DOI":"10.1371\/journal.pone.0301716","volume":"19","author":"KE Blankart","year":"2024","unstructured":"Blankart KE, Vandoros S (2024) Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation. PLOS ONE 19(5):e0301716. https:\/\/doi.org\/10.1371\/journal.pone.0301716. lastaccessed06.09.2024","journal-title":"PLOS ONE"},{"key":"3615_CR6","unstructured":"Bundesbank (2024) Purchasing power equivalents of historical amounts in German currencies: https:\/\/www.bundesbank.de\/de\/statistiken\/konjunktur-und-preise\/-\/kaufkraftaequivalente-historischer-betraege-in-deutschen-waehrungen-615162. last accessed: 29.08.2024"},{"key":"3615_CR7","doi-asserted-by":"publisher","unstructured":"Burt C (2002) National trends in use of medications in office- based practice from 1985 to 1999. https:\/\/doi.org\/10.1377\/hlthaff.21.4.206","DOI":"10.1377\/hlthaff.21.4.206"},{"key":"3615_CR8","doi-asserted-by":"crossref","unstructured":"Carney G, Kim JD, O\u2019Sullivan C, Thompson W, Bassett K, Levin J, Dormuth CR (2022) Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada. BMJ Open Diabetes Res Care. https:\/\/pubmed.ncbi.nlm.nih.gov\/36356988\/","DOI":"10.1136\/bmjdrc-2022-002995"},{"key":"3615_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS II Study","year":"1999","unstructured":"CIBIS II Study (1999) The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 353:9\u201313","journal-title":"Lancet"},{"key":"3615_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enala-pril Survival Study (CONSENSUS). New Engl J Med 316:1429\u20131435","journal-title":"New Engl J Med"},{"key":"3615_CR11","doi-asserted-by":"crossref","unstructured":"Cosin J, Diez J, TORIC investigators (2003) Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4: 507-513","DOI":"10.1016\/S1388-9842(02)00122-8"},{"key":"3615_CR12","doi-asserted-by":"publisher","unstructured":"Dammann, Blum, Lux, Rehner, Riecken, Schiessel, Wienbeck, Witzel (Editorial Board), Berger (Statistik) (1986) Differences in healing tendency of reflux oesophagitis with omeprazol and ranitidine. Results of an Austrian-German-Swiss multicenter trial. Dtsch Med Wochenschr 111(4):123-128. https:\/\/doi.org\/10.1055\/s-2008-1068412","DOI":"10.1055\/s-2008-1068412"},{"issue":"1","key":"3615_CR13","doi-asserted-by":"publisher","first-page":"e000230","DOI":"10.1136\/openhrt-2014-000230","volume":"21","author":"JJ DiNIcolantonio","year":"2015","unstructured":"DiNIcolantonio JJ, Fares H, Niazi AK et al (2015) \u00df-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 21(1):e000230","journal-title":"Open Heart"},{"key":"3615_CR14","unstructured":"Eckert N (2013) Hypothyroidism - or not? When the thyroid gland needs thyroxine. https:\/\/deutsch.medscape.com\/artikel\/4901614, last accessed on 15.04.2024"},{"key":"3615_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1161\/01.CIR.92.5.1326","volume":"92","author":"C Furberg","year":"1995","unstructured":"Furberg C, Psaty BM, Meyer JS (1995) Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326\u20131331","journal-title":"Circulation"},{"key":"3615_CR16","doi-asserted-by":"crossref","unstructured":"Jones P, Kafonek S, Laurora I, Hunninghake D for the CURVES Investigators (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The Curves Study). Am J Cardio!' 81: 582-587","DOI":"10.1016\/S0002-9149(97)00965-X"},{"key":"3615_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jama.299.7.769","volume":"299","author":"J Jonklaas","year":"2008","unstructured":"Jonklaas J, Davidson B, Bhagat S, Soldin SJ (2008) Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 299:769\u2013777","journal-title":"JAMA"},{"key":"3615_CR18","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1055\/s-0043-125340","volume":"56","author":"H Koop","year":"2018","unstructured":"Koop H (2018) Prescribing practice and risks of proton pump blockers - fiction and fact? Z Gastroenterol 56:264\u2013274","journal-title":"Z Gastroenterol"},{"key":"3615_CR19","first-page":"C1940","volume":"99","author":"J Labenz","year":"2002","unstructured":"Labenz J, Petersen K-U, R\u00f6sch W, Koelz H (2002) Selection of proton pump inhibitors. Dtsch \u00c4rtebl 99:C1940\u2013C1944","journal-title":"Dtsch \u00c4rtebl"},{"key":"3615_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","volume":"76","author":"M Lassalle","year":"2020","unstructured":"Lassalle M, Le Tri T, Bardou M et al (2020) Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 76:449\u2013457. https:\/\/doi.org\/10.1007\/s00228-019-02810-1","journal-title":"Eur J Clin Pharmacol"},{"key":"3615_CR21","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R(2021) Drug prescription report 2021: Springer, Berlin\/Heidelberg"},{"key":"3615_CR22","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R (2022) Drug prescription report 2022: Springer, Berlin\/Heidelberg"},{"key":"3615_CR23","unstructured":"Ludwig W, M\u00fchlbauer B, Seifert R (2023) Drug prescription report 2023: Springer, Berlin\/Heidelberg"},{"key":"3615_CR24","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.clinthera.2009.08.010","volume":"31","author":"K Makarounas-Kirchmann","year":"2009","unstructured":"Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P (2009) Results of a metaanalysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther 31:1652\u20131663","journal-title":"Clin Ther"},{"issue":"7","key":"3615_CR25","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, Red\u00f3n J, Zanchetti A, B\u00f6hm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F (2013) Task Force Members (2013): 2013 ESH\/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 31(7):1281\u2013357. https:\/\/doi.org\/10.1097\/01.hjh.0000431740.32696.cc","journal-title":"J Hypertens."},{"key":"3615_CR26","doi-asserted-by":"crossref","unstructured":"Menzies-Gow AN, Tran TN, Stanley B, Carter VA, Smolen JS, Bourdin A, Fitzgerald JM, Raine T, Chapaneri J, Emmanuel B, Jackson DJ, Price DB (2024) Trends in systemic glucocorticoid utilization in the United Kingdom from 1990 to 2019: a population-based, serial cross-sectional analysis. https:\/\/pubmed.ncbi.nlm.nih.gov\/38505738\/ , last accessed 06.09.2024","DOI":"10.2147\/POR.S442959"},{"key":"3615_CR27","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"MERIT-HF Study","year":"1999","unstructured":"MERIT-HF Study (1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomized intervention trial in congestive heart failure. Lancet 353:2001\u20132007","journal-title":"Lancet"},{"key":"3615_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF (2018) Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol 71:1474\u20131482","journal-title":"J Am Coll Cardiol"},{"key":"3615_CR29","first-page":"477","volume":"113","author":"J M\u00f6ssner","year":"2016","unstructured":"M\u00f6ssner J (2016) Indications, benefits and risks of proton pump inhibitors. A review after 25 years. German Med J 113:477\u2013483","journal-title":"German Med J"},{"key":"3615_CR30","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ, Investigators CAMELOT (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292:2217\u20132225","journal-title":"JAMA"},{"key":"3615_CR31","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0149-2918(99)80007-1","volume":"21","author":"LL Noe","year":"1999","unstructured":"Noe LL, Vreeland MG, Pezzella SM, Trotter JP (1999) A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther. 21:854\u2013866","journal-title":"Clin Ther."},{"key":"3615_CR32","doi-asserted-by":"publisher","unstructured":"Olfson M, Shuai Wang, Miren Iza, Stephen Crystal, Carlos Blanco (2013) National trends in the office-based prescription of schedule ii opioids - PMC (nih.gov). J Clin Psychiatry . 74(9):932-9.\u00a0https:\/\/doi.org\/10.4088\/JCP.13m08349. last accessed 04\/15\/2023","DOI":"10.4088\/JCP.13m08349"},{"key":"3615_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ando.2023.03.008","volume":"84","author":"L Persani","year":"2023","unstructured":"Persani L, dell\u2019Acqua M, Ioakim S et al (2023) Factitious thyrotoxicosis and thyroid hormone misuse or abuse. Ann Endocrinol 84:367\u2013369","journal-title":"Ann Endocrinol"},{"key":"3615_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s41969-020-00114-9","volume":"13","author":"S Pilz","year":"2020","unstructured":"Pilz S, Theiler-Schwarz V, Malle O et al (2020) Hypothyroidism: guidelines, new findings and clinical practice. J Clin Endocrinol Stoffw 13:88\u201395","journal-title":"J Clin Endocrinol Stoffw"},{"key":"3615_CR35","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, Martinez FA et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial \u2013 the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582\u20131587","journal-title":"Lancet"},{"key":"3615_CR36","doi-asserted-by":"publisher","unstructured":"Rudolph UM, Enners S, Kieble M, Mahfoud F, B\u00f6hm M, Laufs U, Schulz M (2021) Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. J Human Hyperten, 35(10), 903\u2013911.\u00a0https:\/\/doi.org\/10.1038\/s41371-020-00425-z, last accessed 06.09.2024","DOI":"10.1038\/s41371-020-00425-z"},{"key":"3615_CR37","doi-asserted-by":"crossref","unstructured":"Saravanan P, Siddique H, Simmons DJ, Greenwood R, Dayan CM (2007) Twenty-four hour hormone profiles of TSH, free T3 and free T4 in hypothyroid patients on combined T3\/T4 therapy. Exp Clin Endocrinol Diabetes 1","DOI":"10.1055\/s-2007-973071"},{"key":"3615_CR38","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383\u20131389","journal-title":"Lancet"},{"key":"3615_CR39","unstructured":"Schwabe U, Ludwig W (2020) Drug prescription report 2020: Springer, Berlin\/Heidelberg"},{"key":"3615_CR40","unstructured":"Schwabe U, Paffrath D (1985) Drug prescription report 1985: Gustav Fischer, Stuttgart"},{"key":"3615_CR41","unstructured":"Schwabe U, Paffrath D (1986) Drug prescription report 1986: Gustav Fischer, Stuttgart"},{"key":"3615_CR42","unstructured":"Schwabe U, Paffrath D (1987) Drug prescription report 1987: Gustav Fischer, Stuttgart"},{"key":"3615_CR43","unstructured":"Schwabe U, Paffrath D (1988) Drug prescription report 1988: Gustav Fischer, Stuttgart"},{"key":"3615_CR44","unstructured":"Schwabe U, Paffrath D (1989) Arzneiverordnungsreport 1989: Gustav Fischer, Stuttgart"},{"key":"3615_CR45","unstructured":"Schwabe U, Paffrath D (1990) Drug prescription report 1990: Gustav Fischer, Stuttgart"},{"key":"3615_CR46","unstructured":"Schwabe U, Paffrath D (1991) Drug prescription report 1991: Gustav Fischer, Stuttgart"},{"key":"3615_CR47","unstructured":"Schwabe U, Paffrath D (1992) Arzneiverordnungsreport 1992: Gustav Fischer, Stuttgart"},{"key":"3615_CR48","unstructured":"Schwabe U, Paffrath D (1993) Drug prescription report 1993: Gustav Fischer, Stuttgart"},{"key":"3615_CR49","unstructured":"Schwabe U, Paffrath D (1994) Drug prescription report 1994: Gustav Fischer, Stuttgart"},{"key":"3615_CR50","unstructured":"Schwabe U, Paffrath D (1995) Drug prescription report 1995: Gustav Fischer, Stuttgart"},{"key":"3615_CR51","unstructured":"Schwabe U, Paffrath D (1996) Drug prescription report 1996: Gustav Fischer, Stuttgart"},{"key":"3615_CR52","unstructured":"Schwabe U, Paffrath D (1997) Drug prescription report 1997: Gustav Fischer, Stuttgart"},{"key":"3615_CR53","unstructured":"Schwabe U, Paffrath D (1998) Drug prescription report 1998: Springer, Berlin\/Heidelberg"},{"key":"3615_CR54","unstructured":"Schwabe U, Paffrath D (1999) Drug prescription report 1999: Springer, Berlin\/Heidelberg"},{"key":"3615_CR55","unstructured":"Schwabe U, Paffrath D (2000) Drug prescription report 2000: Springer, Berlin\/Heidelberg"},{"key":"3615_CR56","unstructured":"Schwabe U, Paffrath D (2001) Drug prescription report 2001: Springer, Berlin\/Heidelberg"},{"key":"3615_CR57","unstructured":"Schwabe U, Paffrath D (2002) Drug prescription report 2002: Springer, Berlin\/Heidelberg"},{"key":"3615_CR58","unstructured":"Schwabe U, Paffrath D (2003) Drug prescription report 2003: Springer, Berlin\/Heidelberg"},{"key":"3615_CR59","unstructured":"Schwabe U, Paffrath D (2004) Drug prescription report 2004: Springer, Berlin\/Heidelberg"},{"key":"3615_CR60","unstructured":"Schwabe U, Paffrath D (2005) Drug prescription report 2005: Springer, Berlin\/Heidelberg"},{"key":"3615_CR61","unstructured":"Schwabe U, Paffrath D (2006) Drug prescription report 2006: Springer, Berlin\/Heidelberg"},{"key":"3615_CR62","unstructured":"Schwabe U, Paffrath D (2007) Drug prescription report 2007: Springer, Berlin\/Heidelberg"},{"key":"3615_CR63","unstructured":"Schwabe U, Paffrath D (2008) Drug prescription report 2008: Springer, Berlin\/Heidelberg"},{"key":"3615_CR64","unstructured":"Schwabe U, Paffrath D (2009) Drug prescription report 2009: Springer, Berlin\/Heidelberg"},{"key":"3615_CR65","unstructured":"Schwabe U, Paffrath D (2010) Drug prescription report 2010: Springer, Berlin\/Heidelberg"},{"key":"3615_CR66","unstructured":"Schwabe U, Paffrath D (2011) Drug prescription report 2011: Springer, Berlin\/Heidelberg"},{"key":"3615_CR67","unstructured":"Schwabe U, Paffrath D (2012) Drug prescription report 2012: Springer, Berlin\/Heidelberg"},{"key":"3615_CR68","unstructured":"Schwabe U, Paffrath D (2013) Drug prescription report 2013: Springer, Berlin\/Heidelberg"},{"key":"3615_CR69","unstructured":"Schwabe U, Paffrath D (2014) Drug prescription report 2014: Springer, Berlin\/Heidelberg"},{"key":"3615_CR70","unstructured":"Schwabe U, Paffrath D (2015) Drug prescription report 2015: Springer, Berlin\/Heidelberg"},{"key":"3615_CR71","unstructured":"Schwabe U, Paffrath D (2016) Drug prescription report 2016: Springer, Berlin\/Heidelberg"},{"key":"3615_CR72","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2017) Drug prescription report 2017: Springer, Berlin\/Heidelberg"},{"key":"3615_CR73","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2018) Drug prescription report 2018: Springer, Berlin\/Heidelberg"},{"key":"3615_CR74","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2019) Drug prescription report 2019: Springer, Berlin\/Heidelberg"},{"key":"3615_CR75","doi-asserted-by":"publisher","unstructured":"Sleight P (2000) The HOPE study (heart outcomes prevention evaluation). J Renin-Angiotensin-Aldoster Syst 1(1):18\u201320. https:\/\/doi.org\/10.3317\/jraas.2000.007","DOI":"10.3317\/jraas.2000.007"},{"key":"3615_CR76","unstructured":"Statement by the Drug Commission of the German Medical Association (2006) Drug prescriptions. Recommendations for rational pharmacotherapy. 21st edition, Deutscher \u00c4rzteVerlag Cologne, pp 907-921"},{"key":"3615_CR77","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamainternmed.2013.11312","volume":"174","author":"PN Taylor","year":"2014","unstructured":"Taylor PN, Iqbal A, Minassian C, Sayers A, Draman MS, Greenwood R, Hamilton W, Okosieme O, Panicker V, Thomas SL, Dayan C (2014) Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 174:32\u201339","journal-title":"JAMA Intern Med"},{"key":"3615_CR80","doi-asserted-by":"publisher","first-page":"406","DOI":"10.11622\/smedj.2013143","volume":"54","author":"DJ Topliss","year":"2013","unstructured":"Topliss DJ, Soh SB (2013) Use and misuse of thyroid hormone. Singapore Med J 54:406\u2013410","journal-title":"Singapore Med J"},{"key":"3615_CR81","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/a-1832-0644","volume":"130","author":"I Vardarli","year":"2022","unstructured":"Vardarli I, Brandenburg T, Heged\u00fcs L et al (2022) A questionnaire survey of German thyroidologists on the use of thyroid hormones in hypothyroid and euthyroid patients: the THESIS (treatment of hypothyroidism in europe by specialists: an international survey) collaborative. Exp Clin Endocrinol Diabetes 130:577\u2013586","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"3615_CR82","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1345\/aph.1M177","volume":"43","author":"KA Wargo","year":"2009","unstructured":"Wargo KA, Banta WM (2009) A comprehensive review of the loop diuretics: should furosemide be the first line? Ann Pharmacother 43:1836","journal-title":"Ann Pharmacother"},{"issue":"19","key":"3615_CR83","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"P Whelton","year":"2018","unstructured":"Whelton P, Carey R, Aronow W et al (2018) ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. JACC. 71(19):127\u2013248. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.006","journal-title":"JACC."},{"issue":"33","key":"3615_CR84","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I (2018) ESC Scientific Document Group (2018): 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 39(33):3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"European Heart Journal"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03615-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:17:13Z","timestamp":1744273033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03615-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3615"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03615-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School () and officially registered as a doctoral thesis project for Lennart Schr\u00f6der. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent for publication is not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Archives of Pharmacology and follows the editorial guidelines for editors acting as authors ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}